Xenon Pharmaceuticals (XENE) Assets Average (2014 - 2026)

Xenon Pharmaceuticals (XENE) has 13 years of Assets Average data on file, last reported at $1.0 billion in Q1 2026.

• On a quarterly basis, Assets Average rose 31.05% year-over-year to $1.0 billion in Q1 2026; TTM through Mar 2026 was $1.0 billion, a 31.05% increase from a year earlier, with the FY2025 full-year figure at $715.7 million, down 18.81% from the prior year.
• Assets Average for Q1 2026 stood at $1.0 billion, up from $620.5 million in the prior quarter.
• Over the last five years, Assets Average for XENE reached as high as $1.0 billion in Q1 2026 and fell as low as $565.0 million in Q1 2022.
• Historically, Assets Average has averaged $765.4 million across 5 years, with a median of $765.0 million in 2022.
• Across the five-year window, Assets Average soared 193.69% in 2022 and decreased 25.45% in 2025, its largest moves.
• Year by year, Assets Average stood at $765.0 million in 2022, then grew by 6.92% to $817.9 million in 2023, then decreased by 0.11% to $817.0 million in 2024, then fell by 24.05% to $620.5 million in 2025, then surged by 62.77% to $1.0 billion in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $1.0 billion in Q1 2026, $620.5 million in Q4 2025, and $641.1 million in Q3 2025.